QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · people with epilepsy
1 finding from 1 review
no estimate extracted
1 study · 7 participants
Very low
Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life · people with eczema
1 finding from 1 review
HRQoL: CFQ, Medical Outcomes Study‐36 Item Short‐Form Health Survey, SF‐36 · people with CKD
Summary of findings: relaxation showed no clear difference in quality of life Quality of Life Index ‐ dialysis version and Medical… compared with control (low certainty).
1 finding from 1 review
Quality of life or psychological well‐being (higher = higher quality of life or psychological well‐being): end‐of‐intervention · older people with depression
1 finding from 1 review
Change from baseline in quality of life CDLQI ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis
1 finding from 1 review
Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis
1 finding from 1 review
Quality of life ‐ intermediate term (1 to 6 months post intervention) EQ‐5Di; SF‐36c,m; WHOQOL‐BREFe,j,n (higher score = better quality of life) · adults with common mental disorders
1 finding from 1 review
General life satisfaction Quality of Life Interview section, scale of 1 to 7 · people with both severe mental illness and substance misuse
1 finding from 1 review
Disease‐specific quality of life
1 finding from 1 review
Intervention not reported
Social confidence, social inclusion, social networks or personalised quality of life measures ‐ no clinically significant change · people with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (mental component) (short‐term) SF‐36 physical component scale from 0 to 100 (higher is better quality of life). · patients with hip osteoarthritis
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy
1 finding from 1 review
Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults
1 finding from 1 review
Quality of life (QOLIE‐89) (1‐ to 3‐month periods) · adults with intractable epilepsy
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · participants with epilepsy (one included study only recruited children with absence epilepsy while another included study recruited both…
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · participants with generalised epilepsy
1 finding from 1 review